EAID-Etron "Asiana Airlines, Air Transport of Finished Russian Vaccine"

[Asia Economy Reporter Yoo Hyun-seok] The transportation of the novel coronavirus (COVID-19) vaccine produced by a Russian vaccine contract manufacturing company, in which EID and ETRON have invested 20 billion KRW to hold a 16.7% stake, has officially begun.

According to Asiana Airlines, the finished Sputnik V COVID-19 vaccine produced by Korea Corus was transported on the cargo flight OZ795 departing Incheon for Moscow at 10:20 AM on the 29th. The Sputnik V COVID-19 vaccine was developed by Russia, and Korea Corus, a subsidiary of GL Rapha, the contract manufacturing company of this vaccine, is producing it domestically. This is the second shipment of Sputnik V to Russia, following the first on the 25th.

GL Rapha signed a supply contract for 150 million doses of the Sputnik V vaccine with the Russian sovereign wealth fund, the Russian Direct Investment Fund (RDIF). Located in Yeongdeungpo-gu, Seoul, GL Rapha entered the pharmaceutical and bio market by acquiring Korea Corus, a pharmaceutical production and R&D company, as a subsidiary in November 2007. The production and supply of the Russian vaccine are handled by its subsidiary Korea Corus. Meanwhile, EID and ETRON completed the board resolution for the investment in the ‘Sputnik Corus No. 1’ partnership in mid-month and completed the payment of 20 billion KRW in investment funds on the 22nd.

The Sputnik V vaccine destined for Russia requires storage and transportation at minus 20°C, and it is known that special attention was paid to maintaining the cold chain throughout the entire transportation process from the production plant to Asiana Airlines Incheon Cargo Terminal, the aircraft, and the Moscow Cargo Terminal.

This content was produced with the assistance of AI translation services.